We will have limited operations from 15:00 Tuesday 24 December 2024 (AEDT) until Thursday 2 January 2025. Find out how to contact us during the holiday period.
The TGA warns advertisers and social media influencers against publicly promoting Ozempic (semaglutide) for weight-loss.
There are consequences if someone is found to have breached, the advertising requirements under the Therapeutic Goods Act 1989 (the Act).
Advertising Ozempic is prohibited
Ozempic is a prescription only medicine and cannot be advertised to the public. Prescription medicines are higher risk medicines and should only be determined as an appropriate treatment option in consultation with a professionally trained medical practitioner, rather than on the basis of consumer advertising.
Advertising to the public is a contravention of the Act that can result in jail time and:
- criminal penalties of up to:
- $888,000 for individuals
- $4.44 million for corporations
- civil penalties of up to:
- $1.11 million for individuals
- $11.1 million for corporations.
Read more in Advertising prescription medicine Ozempic (semaglutide) is prohibited.
